Lepodisiran clinical trials
Also written LY3819469.
Includes 1 study of Lepodisiran sodium.
ClinicalTrials.gov finds 4 studies for lepodisiran. How that becomes 8 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives lepodisiran. Its counts are asked again every night. How drug pages count
- 4Found by its intervention search · See all 4 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 4 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +4Give it under a name that search misses: a biosimilar’s code or a misspelling
- 8Give lepodisiran to participants
- 8Test it: the count on this site
Get an email when these change. Save the lepodisiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test lepodisiran.
- Mar 2027A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Phase 1 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses lepodisiran has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 8
- A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)RecruitingPhase 1Eli Lilly and CompanyNCT07914738Injection sites compared in people with high Lp(a)Written as LY3819469How we knowReport a problem
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskRecruitingPhase 3Eli Lilly and CompanyNCT07613294On coronary plaque in high Lp(a)Written as LepodisiranHow we knowReport a problem
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06292013On major cardiovascular events (ACCLAIM-Lp(a))Written as Lepodisiran SodiumHow we knowReport a problem
- A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT06916078In hepatic impairmentWritten as LepodisiranHow we knowReport a problem
- A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]CompletedPhase 2Eli Lilly and CompanyNCT05565742Dose finding in high Lp(a) (ALPACA)Written as LY3819469How we knowReport a problem
- A Study of LY3819469 in Participants With Impaired and Normal Renal FunctionCompletedPhase 1Eli Lilly and CompanyNCT05841277In renal impairmentWritten as LY3819469How we knowReport a problem
- A Study to Compare Two Formulations of LY3819469 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05932446Two formulations comparedWritten as LY3819469How we knowReport a problem
- A Study of LY3819469 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04914546First in human, in healthy participantsWritten as LY3819469How we knowReport a problem
Tested on its own · 8 — no other medicine in its arm
- A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)RecruitingPhase 1Eli Lilly and CompanyNCT07914738Injection sites compared in people with high Lp(a)Written as LY3819469How we knowReport a problem
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskRecruitingPhase 3Eli Lilly and CompanyNCT07613294On coronary plaque in high Lp(a)Written as LepodisiranHow we knowReport a problem
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06292013On major cardiovascular events (ACCLAIM-Lp(a))Written as Lepodisiran SodiumHow we knowReport a problem
- A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT06916078In hepatic impairmentWritten as LepodisiranHow we knowReport a problem
- A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]CompletedPhase 2Eli Lilly and CompanyNCT05565742Dose finding in high Lp(a) (ALPACA)Written as LY3819469How we knowReport a problem
- A Study of LY3819469 in Participants With Impaired and Normal Renal FunctionCompletedPhase 1Eli Lilly and CompanyNCT05841277In renal impairmentWritten as LY3819469How we knowReport a problem
- A Study to Compare Two Formulations of LY3819469 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05932446Two formulations comparedWritten as LY3819469How we knowReport a problem
- A Study of LY3819469 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04914546First in human, in healthy participantsWritten as LY3819469How we knowReport a problem
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Nov 17, 2026NCT07914738
Newly registered1
- A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Nov 4, 2026NCT07914738
Codes
What other systems call lepodisiran · ClinicalTrials.gg INT018428
- UNII (FDA) X4BE7S8PN9LEPODISIRANOne source FDA
- NCI Thesaurus C203143LepodisiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X4BE7S8PN9 | LEPODISIRAN | One source FDA |
| NCI Thesaurus | C203143 | Lepodisiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.